pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Alzheimer's Disease
drug
save

Alzheimer's Disease

Preclinicalupdated 6mo ago
by Metallomix Inc
Preclinical
community read0 votes

🐶 often sniffed alongside

top 8
  • tagAlzheimer's Disease51 co-mentions · 50 sources
  • companyNorthwestern University3 co-mentions · 3 sources
  • companyEmory University2 co-mentions · 2 sources
  • companyUniversity of Florida2 co-mentions · 2 sources
  • companyMassachusetts General Hospital2 co-mentions · 2 sources
  • companyWake Forest University1 co-mentions · 1 sources
  • drugbupropion hydrochloride ER1 co-mentions · 1 sources
  • drugBUPROPION HYDROCHLORIDE1 co-mentions · 1 sources

indications

indications
Alzheimer's Disease

all catalysts(0)

nothing on the calendar yet

Trials studying Alzheimer's Disease

  • N/AEstablishing Clinical Utility Evidence for a Novel Alzheimer's Disease Blood-Based Biomarker Assaycompletedn=178
  • EP1Preliminary Clinical Trial- FallScape-Dactive not recruitingn=24

News(10)

  • Biogen’s tau therapy drives bigger benefits in 2-year Alzheimer’s update
    Biogen has linked its tau-targeting antisense oligonucleotide to a further slowing of clinical decline after two years, leading analysts to hail the strengthening of evidence supporting late-phase…
    fiercebiotech · 6h ago
  • Priavoid’s Alzheimer’s pill fails to prove efficacy in phase 2 trial
    Priavoid’s pill for Alzheimer's disease has failed to prove its effectiveness in a phase 2 dementia study, although the German biotech pointed to encouraging signs in the longer-term data.
    fiercebiotech · 11h ago
  • Cognito phase 3 flops in light-and-sound Alzheimer's trial, but sees ‘signal’ for HOPE
    Cognito Therapeutics said its phase 3 HOPE study of Spectris AD, an investigational, non-invasive, at-home Alzheimer's therapy that uses light and sound stimulation to engage brain activity, failed…
    fiercebiotech · 12h ago
  • #CTAD26: Cognito plans FDA submission of light and sound therapy for Alzheimer’s
    BOSTON — A decade ago, neuroscientists at MIT published data that seemed too good, or perhaps just too wacky, to be true. Light flickered at just the right frequency induced brain waves that appear…
    endpoints · 1d ago
  • CTAD 2026: AriBio’s Alzheimer’s candidate slows cognitive decline as monotherapy
    At the 2026 Clinical Trials on Alzheimer’s Disease conference, AriBio reported that AR1001 slowed cognitive decline more than placebo in patients not taking other drugs for the disease.
    biospace · 1d ago
  • AriBio’s oral Alzheimer’s drug meets monotherapy goal in phase 3 as Fosun weighs licensing option
    AriBio’s erectile dysfunction med-turned Alzheimer’s disease candidate mirodenafil has delivered some mixed results from a global phase 3 trial. Fosun Pharma has an option to in-license the PDE5 in…
    fiercebiotech · 1d ago
  • J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depression
    Delix Therapeutics has raised $100 million in a series C round backed by the likes of Johnson & Johnson to advance a phase 2-ready non-hallucinatory psychedelic therapy for depression.
    fiercebiotech · 9d ago
  • This week in charts: 3 drug launches Wall Street is watching
    The latest installment in BioPharma Dive’s visualization-focused series features a look at investors’ response to a trio of medicines highlighted in quarterly earnings this week.
    biopharma_dive · 12d ago
  • Eli Lilly scraps phase 2 Alzheimer's program after drug falls short of expectations
    Eli Lilly has dropped its phase 2 Alzheimer's disease program for mevidalen, marking another setback for the experimental drug as the Big Pharma expands its neuroscience pipeline through multibilli…
    fiercebiotech · 20d ago
  • BMS walks away from $80M neurodegeneration bet after phase 1
    Bristol Myers Squibb has scrapped a phase 1 program it bet $80 million on just two years ago.
    fiercebiotech · 20d ago
view all news mentions →
indication
Alzheimer's Disease
phase
preclinical
Data sources
ClinicalTrials.gov
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?